ERBB2 and breast cancer: Despite some undisputed successes and promising expectations coming from the new anti-HER2 agents in HER2-low BC, to the point where two phase 3 trials are already ongoing, this new treatment strategy underlines the steep road of cancer drug development, characterized by complex technologies, the important commitment of multiple stakeholders and, oftentimes, clinical outcomes not always fulfilling preclinical expectations.